Floatz logo

CITALOPRAM

Comorbidity

Massachusetts General HospitalSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Comorbidity cohort.

Asset / SponsorPhaseRating
Vilazodone
Massachusetts General Hospital
Phase 4B

Same molecule, other indications

CITALOPRAM is also rated in:

Bipolar I DisorderDormant
BBB
Indicative ·
77 / 100
View asset →
bipolar disorderDormant
BBB
Indicative ·
74 / 100
View asset →
depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →